MannKind Corporation (MNKD)
Symbol Info
Listed Symbol MNKD
Name MannKind Corporation
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $27,859,000
Latest Fiscal EPS $-0.61
Price Info
21 Day Moving Average $1.2902
21 Day EMA $1.280630
50 Day Moving Average $1.2292
50 Day EMA $1.251450
200 Day EMA $1.367190
200 Day Moving Average 1.369380
52 Week High $2.34
52 Week Low $0.94
52 Week Change $-37.561000
Alpha -0.033629
Beta 2.3314
Standard Deviation 0.272556
R2 0.086293
Periods 60
Share Information
10 Day Average Volume 1,277,206
20 Day Average Volume 1,725,011
30 Day Average Volume 2,169,186
50 Day Average Volume 2,276,379
Outstanding Shares 189,616,126
Float Shares 184,927,047
Percent Float 97.53%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 219
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 4,769,717
Institute Holdings Percent 39.800000
Institute Sold Previous 3 Months 5,547,480
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 6
Insider Holdings Percent 2.50%
Insider Sold Previous 3 Months 1
Insiders Shares Owned 4,689,079
Price Change
7 Day Price Change $-
7 Day Percent Change -
21 Day Price Change $0.0300000
21 Day Percent Change 2.40%
30 Day Price Change $-0.0600001
30 Day Percent Change -4.48%
Month To Date Price Change $0.0300
Month To Date Percent 2.40%
90 Day Price Change $0.210000
90 Day Percent Change 19.63%
Quarter To Date $0.030000
Quarter To Date Percent 2.40%
180 Day Price Change $-0.25
180 Day Percent Change -16.34%
200 Day Price Change $-0.52
200 Day Percent Change -28.89%
Year To Date $0.220000
Year To Date Percent 20.75%
Profile
Description MannKind Corp is a biopharmaceutical company. It is involved in the business of discovery, development, and commercialization of therapeutic products and solutions for the patients with the diseases such as diabetes. Its products and technologies include Afrezza, Dry powder formulation, Inhalation profiling, Oral inhalers and others. The company has following products in the pipeline: Epinephrine technosphere, Treprostinil technosphere, and Palonosetron technosphere.
Details
Issue Type CS
Market Cap $242,708,641
Sec Type EQS
Auditor Deloitte & Touche LLP
Total Shares Outstanding 189,616,126
CEO Michael E. Castagna
Employees 225
Last Audit UE
Classification
CIK 0000899460
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 30930 Russell Ranch Road
Suite 300
Westlake Village, CA 91362
Website http://www.mannkindcorp.com
Facisimile
Telephone +1 818 661-5000
Email
Key Ratios
Profitability
EBIT Margin -102.1
EBITDA Margin -96.9
Pre-Tax Profit Margin -
Profit Margin Cont -76.28
Gross Margin 55.80
Profit Margin TOT -76.28
Income Statements
Revenue $48,535,000
Revenue Per Share $0.2560
Revenue 3 Years $-39.79
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $307,223,157
Price To Sales 5.000693
Price To Free Cash -28.7
PE High Last 5 Years -
Price To Book 187.9
Price To Cash Flow 26.5
PE Low Last 5 Years -
Price To Tangible Book -1.2
Financial Strength
Total Debt To Equity -
Int Coverage -7.6
Current Ratio 0.6
Leverage Ratio -0.7
Quick Ratio 0.5
Long Term Debt To Capital -
Assets
Receivables Turnover 6.5
Invoice Turnover 6.90
Assets Turnover 0.30
Management Effectiveness
Return Assets -85.01
Return On Equity 30.39
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
MNKD
MannKind
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.